trial · primary record
KAT-101
Hepatocellular Carcinoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 1 |
| Primary completion | 2022-12-26 |
| Primary endpoint | To determine the Recommended Phase 2 Dose (RP2D) for oral + IT administration |
| Registry ID | NCT05603572 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:37.449Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05603572
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.